NASDAQ:KOOL - Cesca Therapeutics Stock Price, Forecast & News

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

Cesca Therapeutics Inc (NASDAQ:KOOL) released its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. View Cesca Therapeutics' Earnings History.

Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Cesca Therapeutics.

1 brokerages have issued 1-year target prices for Cesca Therapeutics' shares. Their forecasts range from $7.50 to $7.50. On average, they expect Cesca Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.

News articles about KOOL stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cesca Therapeutics earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Cesca Therapeutics.

Some companies that are related to Cesca Therapeutics include NanoViricides (NNVC), PLx Pharma (PLXP), Psychemedics (PMD), Idera Pharmaceuticals (IDRA), Protalix Biotherapeutics (PLX), Avacta Group (AVCT), Oventus Medical (OVN), BARD1 Life Sciences (BD1), T2 Biosystems (TTOO), Impression Healthcare (IHL), Zafgen (ZFGN), Bioanalytical Systems (BASI), SUMMIT THERAPEU/S (SMMT), Tiziana Life Sciences (TILS) and Curis (CRIS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Synergy Pharmaceuticals (SGYP), AEterna Zentaris (AEZS), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI) and Amicus Therapeutics (FOLD).

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KOOL stock can currently be purchased for approximately $5.00.

Cesca Therapeutics has a market capitalization of $12.10 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.View Additional Information About Cesca Therapeutics.

The official website for Cesca Therapeutics is http://www.cescatherapeutics.com/.

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]